Strategic Acquisitions, Clinical Data Presentations, Research Grants, and Technical Updates - Analyst Notes on Acadia, Opko Health, Arrowhead Research, Agios Pharmaceuticals and Sangamo Biosciences

NEW YORK, June 6, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Acadia Healthcare Company, Inc. (NASDAQ: ACHC), Opko Health, Inc. (NYSE: OPK), Arrowhead Research Corp. (NASDAQ: ARWR), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3420-100free.

--
Acadia Healthcare Company, Inc. Analyst Notes
On June 3, 2014, Acadia Healthcare Company, Inc. (Acadia) announced that it has signed a definitive agreement for the acquisition of Partnerships in Care (PiC). Acadia informed that it will acquire PiC for an estimated $660 million in cash, and expects the transaction to be completed by July 1, 2014. Joey Jacobs, Acadia Chairman and CEO, stated, "We believe our combination with PiC will be a great transaction for both Acadia and PiC. We expect to support PiC's strong management team in taking advantage of additional growth opportunities in the UK through both our access to capital and the expertise evident in the successful long-term growth record of Acadia's management team." The full analyst notes on Acadia are available to download free of charge at:

http://www.analystsreview.com/Jun-06-2014/ACHC/report.pdf

--
Opko Health, Inc. Analyst Notes
On May 20, 2014, Opko Health, Inc. (Opko Health) announced that it will present new clinical data at the ICE/Endo 2014, on its long-acting human growth hormone product (hGH-CTP). According to the Company, the data will be presented by OPKO Biologics (formerly PROLOR Biotech) scientists at the aforesaid event- the joint meeting of The Endocrine Society and The International Congress of Endocrinology on June 21 to June 24, 2014, in Chicago. Opko Health informed that the data to be presented include results from the Company's phase 2 trial, which is a one year dose finding study administering hGH-CTP to growth hormone deficient children once a week using daily hGH as a comparator arm. Additionally, the Company stated that it will hold a clinical workshop and present top line six month efficacy data from the Phase 2 trial to endocrinologists participating in the hGH-CTP clinical studies. In other news dated May 22, 2014, the Company reported that it has completed the acquisition of Inspiro Medical Ltd., an Israeli medical device company. The full analyst notes on Opko Health are available to download free of charge at:

http://www.analystsreview.com/Jun-06-2014/OPK/report.pdf

--
Arrowhead Research Corp. Analyst Notes
On June 3, 2014, Arrowhead Research Corp.'s (Arrowhead Research) stock reflected an increase of 7.33%, closing the day at $12.88. Over the past six month of trading, Arrowhead Research stock has increased by 42.95% compared to the Nasdaq Composite which has gained 4.67%, during the same trading period. The full analyst notes on Arrowhead Research are available to download free of charge at:

http://www.analystsreview.com/Jun-06-2014/ARWR/report.pdf

--
Agios Pharmaceuticals, Inc. Analyst Notes
On June 3, 2014, Agios Pharmaceuticals, Inc.'s stock went up 9.09%, to close the day's trading at $36.76. Over the previous one month of trading however, the Company's stock has lost 15.06% compared to the Nasdaq Composite which has increased 2.67%, during the same trading period. The full analyst notes on Agios Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jun-06-2014/AGIO/report.pdf

--
Sangamo Biosciences Inc. Analyst Notes
On May 30, 2014, Sangamo Biosciences Inc. (Sangamo Biosciences) announced that it has been granted $5.6 million Strategic Partnership Award by the California Institute for Regenerative Medicine (CIRM). According to the Company, the four-year grant will fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of the Company's zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs). Sangamo BioSciences' President and CEO, Edward Lanphier, remarked, "This is the first of several clinical applications of ZFN-based technology in stem cells. Results of this research can be expected to have a wide effect on the field, enhancing the impact of CIRM-funded research in multiple disease areas and applications, including our beta-thalassemia and sickle cell disease programs which are currently in preclinical development." The full analyst notes on Sangamo Biosciences are available to download free of charge at:

http://www.analystsreview.com/Jun-06-2014/SGMO/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED